

# HMN-214

Catalog No: tcsc0202



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

173529-46-9

**Formula:**

$C_{22}H_{20}N_2O_5S$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

Polo-like Kinase (PLK)

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

IVX-214

**Observed Molecular Weight:**

424.47


## Product Description

HMN-214, an orally bioavailable prodrug of HMN-176, is an inhibitor of polo-like kinase-1 (**plk1**), with antitumor activity.

IC50 & Target: PLK1<sup>[2][4]</sup>

**In Vitro:** HMN-214 is a prodrug of HMN-176. HMN-176 shows potent activities against 22 human tumor cell lines, with a mean IC<sub>50</sub>s of 118 nM<sup>[1]</sup>. HMN-176 (3-300 nM) inhibits luciferase expression driven by the MDR1 promoter in a dose dependent manner in HeLa cells. HMN-176 (30-3000 nM) also dose-dependently suppresses complex formation on the Y-box<sup>[3]</sup>. HMN-214 (3.3 μM) enhances luciferase expression relative to vehicle control with the 1,4C-1,4Bis polymer (11-fold) and PEI (37-fold) in PC3-PSMA cells. HMN-214 (≥ 3.3 μM) significantly reduces cell proliferation, causes considerable changes in cell morphology in MB49 cells<sup>[4]</sup>.

**In Vivo:** HMN-214 (33 mg/kg, p.o.) converts to HMN-176 in rats. HMN-214 has no effect on the conduction velocity and the amplitude of action potentials in the sciatic and tibial nerves. HMN-214 (20 mg/kg, p.o.) exhibits antitumor activity in mice<sup>[1]</sup>. HMN-214 (10, 20 mg/kg, p.o.) decreases MDR1 mRNA expression in nude mice bearing KB- and KB-A.1.-derived tumors<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!